Follistatin 315
Also known as: FST-315, FS-315, FS315, Follistatin-315, FST315, hFS-315, rhFS-315
Endogenous glycoprotein; activin-binding protein; TGF-β superfamily antagonist
What it is
Researchers study Follistatin-315 for its role in muscle growth, liver regeneration, and bone repair by blocking the body's natural muscle-limiting signals. It's investigated as a potential therapy for muscle wasting diseases. No FDA-approved therapeutic use; prohibited by WADA; evidence comes primarily from animal models and lab studies.
The scientific side
Follistatin 315 (FS-315) is a 315 amino acid glycoprotein originating from an alternatively spliced mRNA of the follistatin gene (PMID 3153465, PMID 3365249). It functions as a high-affinity activin-binding protein that neutralizes the biological actions of activin by forming an inactive complex. FS-315 has a lower affinity for activin A (Kd ~432 pM) compared to FS-288 (Kd ~46.5 pM), and accordingly shows weaker inhibition of activin-induced transcriptional responses. Unlike the truncated FS-288 isoform, FS-315 possesses a 27 amino acid carboxyl-terminal extension that confers no affinity for cell-surface heparan sulfate proteoglycans, causing it to be secreted freely into the medium rather than remaining cell-surface-associated. FS-315 can also bind and antagonize other TGF-β superfamily members including myostatin, thereby influencing muscle mass. In the liver, FS-315 has been reported to block activin A-mediated inhibition of hepatocyte proliferation and may promote liver regeneration. Additionally, follistatin-315 blunts hepcidin induction by inflammatory stimuli in vivo by inhibiting activin B-driven SMAD1/5/8 signaling.
Class: Endogenous glycoprotein; activin-binding protein; TGF-β superfamily antagonist
Administration & storage
- Administration
- Intravenous infusion in rats (PMID: 15782995)Intramuscular injection via recombinant AAV vector in mice (PMID: 33869993)
- Storage
- No specific storage conditions for FS-315 are described in the reviewed abstracts.
- Cautions
- No approved pharmaceutical formulations of follistatin are currently available; black market products labeled 'follistatin 315' or 'follistatin 344' have been found to contain His-tagged recombinant protein, oligomers, and in some cases unrelated peptides such as MGF or GHRP-2 rather than follistatin.,FS-315 is prohibited under WADA 2019 List of Prohibited Substances and Methods, chapter S4.,Native FST315 has poor pharmacokinetic properties when administered parenterally, with very short half-life and low systemic exposure in animal models; dose-response relationships are not well characterized for exogenous administration.,Mice expressing only FST-315 (lacking FST-288) showed reproductive abnormalities including reduced follicles, absent corpora lutea, and ovarian-uterine inflammation, indicating that isoform balance is important for reproductive health.,Sterile technique is required for any injectable preparation to prevent contamination and infection risk.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. No approved pharmaceutical formulations noted in reviewed literature.
Prohibited — listed under chapter S4 of the WADA 2019 List of Prohibited Substances and Methods.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Muscle hypertrophy / muscle wasting diseases Animal studies only
- AAV delivery of FS344 cDNA produces a 315 amino acid secreted peptide that increased muscle mass and strength in mice and non-human primates without observed adverse effects on the reproductive axis or organ pathology in preclinical models. PMID 19208403 Rodino-Klapac et al., Muscle & Nerve (2009)
- Native FST315 was found to have poor PK/PD properties for systemic therapeutic use; an engineered Fc-fusion variant with heparan sulfate-binding ablation showed ~100-fold improvement in half-life and robust dose-dependent muscle effects in mouse models of atrophy. PMID 23249626 Datta-Mannan et al., J Pharmacol Exp Ther (2013)
- Intramuscular AAV-FST-315 and AAV-FST-288 both induced muscle hypertrophy and altered adjacent bone geometry (tibial crest lengthening, cortical bone resorption) in young adult male C57BL/6J mice. PMID 33869993 Chan et al., JBMR Plus (2021)
- Follistatin expression was significantly higher in Mdx (Duchenne muscular dystrophy model) mice than controls, with coincident expression with myostatin, suggesting follistatin's potential role in combating muscle loss during dystrophies. PMID 19715499 Abe et al., Zoological Science (2009)
- Liver regeneration Animal studies only
- Intravenous injection of FS-315 at 72 hours post-70% partial hepatectomy resulted in more potent stimulation of DNA synthesis and greater increase in body weight compared to controls in rats. PMID 15782995 Takamura et al., Hepato-gastroenterology (2005)
- Both FS-288 and FS-315 mRNA levels increased from 3 h, peaked at 6 h, and remained elevated up to 12 h following CCl4-induced liver injury in rats, suggesting a role in early liver regeneration. PMID 10864030 Kobayashi et al., Biol Pharm Bull (2000)
- Regulation of hepcidin / anemia of inflammation Animal studies only
- Follistatin-315 blunted hepcidin induction by LPS and B. abortus in mice, supporting a functional role for inhibiting activin B-driven SMAD1/5/8 signaling in hepcidin regulation during inflammation. PMID 26735394 Canali et al., Endocrinology (2016)
- Bone repair / tissue engineering Mixed
- In vitro, FST promoted MSC and endothelial cell migration and vascularization steps. In vivo, FST315 loaded in alginate/collagen microspheres released over 4 weeks in a rat calvarial defect model but did not improve bone healing compared to control. PMID 30881954 Fahmy-Garcia et al., Frontiers in Bioengineering and Biotechnology (2019)
- Ovarian function and follicular development Mixed
- Review discussing both FS-288 and FS-315 isoforms and their roles in modulating activin and other TGF-β superfamily members in ovarian biology. PMID 12887271 Lin et al., Reproduction (2003)
- Granulosa cells contained three FS-315 mRNA transcripts for each FS-288 transcript; neither isoform varied significantly across follicle sizes analyzed in normal women or in polycystic ovary syndrome. PMID 11549651 Fujiwara et al., J Clin Endocrinol Metab (2001)
- Female mice lacking endogenous follistatin but expressing only the FST-315 transgene showed reproductive abnormalities (reduced follicles, no corpora lutea, inflammation), demonstrating that FST-288 is required for normal reproductive tract development and function. PMID 24630125 Holdsworth-Carson et al., Reprod Fertil Dev (2015)
- Hepatic insulin sensitivity and lipid metabolism Animal studies only
- FST288-only mice (lacking circulating FST-315 isoform) exhibited extensive hepatic steatosis, elevated triglyceride content, and paradoxically enhanced insulin signaling, suggesting FST-315 plays a role in regulating hepatic activin bioavailability and lipid homeostasis. PMID 23533219 Ungerleider et al., Endocrinology (2013)
- Porcine embryo pre-implantational development Animal studies only
- 1 ng/mL FST-315 significantly increased total cell numbers and trophectoderm cell numbers in porcine parthenogenetically activated blastocysts; FST-315 improved blastocyst quality whereas FST-300 improved blastocyst formation rate. PMID 29119699 Li et al., Animal Science Journal (2018)
Safety signals
- Black market products labeled 'follistatin 315' have been found to contain not only His-tagged recombinant protein and its oligomers but also unrelated growth-promoting peptides (e.g., MGF, GHRP-2), indicating significant product adulteration and quality concerns. PMID 31758732
- Female mice expressing only FST-315 (tghFST315, lacking FST-288) developed reproductive abnormalities including reduced follicles, absence of corpora lutea, ovarian-uterine inflammation, disorganized myometrium, and reduced endometrial gland number. PMID 24630125
- FST288-only mice (with elevated circulating activin due to loss of the FST-315 isoform) developed extensive hepatic steatosis and elevated hepatic triglyceride content, suggesting that FST-315 is required for normal hepatic lipid homeostasis. PMID 23533219
- Native FST315 was found to have intrinsic PK/PD properties poorly suited for parenteral systemic use, including rapid clearance, which may lead to unpredictable exposure-response relationships. PMID 23249626
- Plasma follistatin (myokine) was elevated in murine sepsis models, suggesting that circulating follistatin levels may reflect or contribute to systemic inflammatory responses. PMID 29979626
Contraindications
- Use in females with reproductive intent: FST-315-only expression (absence of FST-288) is associated with severe reproductive tract abnormalities in mice, including follicular loss, absent corpora lutea, and uterine/oviductal inflammation. PMID 24630125
- Pre-existing hepatic steatosis or hepatic lipid metabolism disorders: loss of circulating FST-315 in animal models led to extensive hepatic steatosis; implications for exogenous administration unknown but relevant. PMID 23533219
Protocol
100 mcg intramuscular, once daily. Cycle: 10-14 days.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravenous | FS 315 infused intravenously (exact dose not specified in abstract) | Single injection at 72 hours post-hepatectomy | animal | Research PMID 15782995 |
| In vitro culture supplementation | 1 ng/mL, 10 ng/mL, or 100 ng/mL FST-315 in embryo culture medium | Throughout in vitro culture (IVC) duration | in_vitro | Research PMID 29119699 |
| Not specified in abstract | Follistatin-315 (dose not specified in abstract) | Not specified | animal | Research PMID 26735394 |
| In vitro | ED50 = 20 ng/mL for suppression of FSH release (FS-315 vs. ED50 2 ng/mL for FS-288) | In vitro cell culture assay | in_vitro | Research PMID 8340384 |
| Subcutaneous (for engineered Fc-fusion variant; native FST315 PK assessed separately) | Native FST315 evaluated in pharmacokinetic and pharmacodynamic studies in mice; specific mg/kg doses not stated in abstract | Not specified | animal | Research PMID 23249626 |
| intramuscular | 100 mcg | once daily · 10-14 days | bodybuilders and strength athletes seeking muscle hypertrophy | [Community] |
| intramuscular | 50 mcg | once daily · 10-14 days | bodybuilders new to follistatin or running a conservative first cycle | [Community] |
| intramuscular | 200 mcg | once daily · 10 days | advanced bodybuilders or competitive athletes pushing hypertrophy | [Community] |
| intramuscular | 100 mcg | every other day · 4 weeks | bodybuilders seeking a longer, lower-intensity protocol | [Community] |
| intramuscular | 100 mcg | once daily · 10 days | users combining follistatin-315 with IGF-1 LR3 or other peptides for synergistic muscle growth | [Community] |
All studies (21)
- PMID 11549651 Mixed
Ovarian function and follicular development - PMID 12887271 Mixed
Ovarian function and follicular development - PMID 24630125 Mixed
Ovarian function and follicular development - PMID 30881954 Mixed
Bone repair / tissue engineering - PMID 1906804
- PMID 3153465
- PMID 3365249
- PMID 8340384
ED50 = 20 ng/mL for suppression of FSH release (FS-315 vs. ED50 2 ng/mL for FS-288) In vitro (in_vitro) - PMID 9395712
- PMID 10864030 Animal studies only
Liver regeneration - PMID 11027950
- PMID 15782995 Animal studies only
Liver regeneration - PMID 19208403 Animal studies only
Muscle hypertrophy / muscle wasting diseases - PMID 19715499 Animal studies only
Muscle hypertrophy / muscle wasting diseases - PMID 23249626 Animal studies only
Muscle hypertrophy / muscle wasting diseases - PMID 23533219 Animal studies only
Hepatic insulin sensitivity and lipid metabolism - PMID 26735394 Animal studies only
Regulation of hepcidin / anemia of inflammation - PMID 29119699 Animal studies only
Porcine embryo pre-implantational development - PMID 29979626
Plasma follistatin (myokine) was elevated in murine sepsis models, suggesting that circulating follistatin levels may reflect or contribute to systemic inflamma - PMID 31758732
Black market products labeled 'follistatin 315' have been found to contain not only His-tagged recombinant protein and its oligomers but also unrelated growth-p - PMID 33869993 Animal studies only
Muscle hypertrophy / muscle wasting diseases
Frequently asked
What is Follistatin 315 and how does it differ from Follistatin 288?
Follistatin 315 (FS-315) is a 315 amino acid glycoprotein isoform of follistatin, arising from alternative mRNA splicing. It differs from FS-288 by having an extra 27 amino acid sequence at the carboxyl-terminal end. This difference has major functional consequences: FS-315 does not bind to cell-surface heparan sulfate proteoglycans and is secreted freely into the circulation, whereas FS-288 binds tightly to cell surfaces. FS-288 also has approximately 10-fold higher affinity for activin A (Kd ~46.5 pM vs. ~432 pM for FS-315) and is more potent at inhibiting FSH secretion in vitro (PMID 11027950, PMID 8340384).
Is Follistatin 315 approved for human use?
Based on the reviewed literature, no approved pharmaceutical formulations of follistatin are currently available for human use. Follistatin 315 is prohibited under the WADA 2019 List of Prohibited Substances and Methods, chapter S4. Regulatory approval status with specific agencies (FDA, Health Canada) is not stated in the reviewed literature and requires manual verification with those agencies.
What dose of Follistatin 315 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: in animal studies, intravenous FS-315 administered post-hepatectomy in rats showed stimulatory effects on liver DNA synthesis; in vitro, 1 ng/mL FST-315 improved porcine blastocyst quality. No human dosing data are available in the reviewed literature. No approved human dosing regimen exists.
Can I stack Follistatin 315 with other peptides or SARMs?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: FST-315 has been studied as a myostatin antagonist in animal models of muscle atrophy (PMID 23249626, PMID 19208403). No combination or stacking studies with other peptides or SARMs were found in the reviewed literature.
Where can I buy Follistatin 315?
I don't recommend vendors or sources. Please consult a licensed provider. Note that black market products labeled 'follistatin 315' have been found to be adulterated or mislabeled, and some contained entirely different peptides.
Does Follistatin 315 build muscle?
Preclinical animal data support a role for follistatin isoforms in muscle hypertrophy. AAV-delivered FST-315 induced muscle hypertrophy in mice. In a gene therapy context, AAV-FS344 (whose transgene product is a 315 amino acid peptide) increased muscle mass and strength in species ranging from mice to monkeys. An engineered FST315-Fc fusion showed dose-dependent muscle effects in mouse models. However, no human clinical trial data for exogenously administered FST-315 protein were found in the reviewed abstracts.
Is Follistatin 315 banned in sports?
Yes. Follistatin is prohibited according to chapter S4 of the WADA 2019 List of Prohibited Substances and Methods. Athletes subject to anti-doping regulations should be aware of this status.
What are the side effects or safety risks of Follistatin 315?
The reviewed literature identifies several safety signals, primarily from animal models: (1) Female mice expressing only FST-315 (lacking FST-288) developed severe reproductive abnormalities including loss of follicles, absent corpora lutea, and uterine/oviductal inflammation. (2) Loss of the circulating FST-315 isoform in mice led to extensive hepatic steatosis. (3) Native FST315 has very poor pharmacokinetics when given parenterally, leading to unpredictable systemic exposure. (4) Black market products labeled 'follistatin 315' have been found adulterated with unrelated peptides such as MGF and GHRP-2. No human safety data were identified in the reviewed abstracts.
Does Follistatin 315 affect FSH or reproductive hormones?
Follistatin 315 has been shown to suppress FSH secretion from rat pituitary cells in vitro, with an ED50 of ~20 ng/mL, which is less potent than FS-288 (ED50 ~2 ng/mL). FS-315 functions as an activin-binding protein and can modulate the hypothalamic-pituitary-gonadal axis. Mice lacking FST-288 and expressing only FST-315 showed significant reproductive abnormalities. Human data on FSH/reproductive hormone effects of exogenous FST-315 administration are not available in the reviewed literature.
Can Follistatin 315 be used for liver disease or liver regeneration?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. In animal research, intravenous FS-315 administered to rats following partial hepatectomy stimulated hepatic DNA synthesis and increased body weight compared to controls, suggesting a potential role in liver regeneration. These are preclinical animal data only; no human data exist in the reviewed literature.